Sources
 Monday Morning Update 6/5/23 – HIStalk
HIStalk - (Monday June 5, 2023) Top News The National Eating Disorder Association shuts down its chatbot after users report that it gave them inappropriate advice for managing eating disorders, such as advising them to diet.  Bonus Features – June 4, 2023 – 51% of hospitals plan to participate in TEFCA, only 18% of orgs have implemented email security software correctly, and more | Healthcare IT Today
Healthcare IT Today - (Sunday June 4, 2023) Welcome to the weekly edition of Healthcare IT Today Bonus Features. This article will be a weekly roundup of interesting stories, product announcements, new hires, partnerships, research studies, awards, sales, and more. Because there’s… |
 INVEST Pitch Perfect Spotlight: How Partum Health Is Working To Transform Maternal Healthcare – MedCity News
MedCity News - (Sunday June 4, 2023) Meghan Doyle (left), CEO of Partum Health, accepts the MedCity INVEST Pitch Perfect award from Arundhati Parmar (right), editor-in-chief of MedCity News, May 24.  How Should Providers Begin to Regulate Their Staff’s Use of ChatGPT? – MedCity News
MedCity News - (Sunday June 4, 2023) The healthcare sector has a reputation of being notoriously slow to adopt new technologies. However, the field doesn’t seem to be immune to the lure of artificial intelligence — including large language models (LLMs),… |
 The Real Pandemic: Mentally Thrive Through Psychological Warfare
eHealth Radio Network - (Saturday June 3, 2023)
 Weekly Roundup – June 3, 2023 | Healthcare IT Today
Healthcare IT Today - (Saturday June 3, 2023) Welcome to our Healthcare IT Today Weekly Roundup. Each week, we’ll be providing a look back at the articles we posted and why they’re important to the healthcare IT community. We hope this gives… |
 Mark Cuban calls Yusimry’s availability on MCCPDC ‘a game changer’
MobiHealthNews - (Saturday June 3, 2023) Mark Cuban Cost Plus Drug Company (MCCPDC) announced it is working with Coherus Biosciences, Inc. to sell Yusimry, a biosimilar version of the top-selling drug Humira, at a discounted price. Yusimry is used to treat…  Mark Cuban expresses excitement for Yusimry’s availability on MCCPDC
MobiHealthNews - (Saturday June 3, 2023) Mark Cuban Cost Plus Drug Company (MCCPDC) announced it is working with global biosimilar company Coherus Biosciences, Inc. to sell Yusimry, a biosimilar version of the top-selling drug Humira, at a discounted price. Yusimry is… |
 Digital Biomarkers: The Key to Delivering on the Promise of Personalized Medicine – MedCity News
MedCity News - (Saturday June 3, 2023) As the healthcare industry strives toward precision medicine, it will be essential for care providers to gain an intimate view of a patient’s response to treatment to determine its impact on their quality of…  Hyro Raises $20M for Conversational AI Assistant Used by Intermountain, Novant & More – MedCity News
MedCity News - (Friday June 2, 2023) Health-focused AI companies are continuing to generate venture capital funding as the healthcare industry works to automate its myriad of time-consuming administrative processes. This week, Hyro — a New York-based startup that is building… |
